SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical…
ERAS-801’s CNS penetration: four times higher than approved EGFR inhibitorsComprehensive inhibition against oncogenic EGFR vIII…
SAN CARLOS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a…
EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage…
New York, NY, and Tel Aviv, ISRAEL, Oct. 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos…
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
MINNEAPOLIS , Oct. 25, 2021 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
First and only orally delivered epinephrine product candidate AQST-109 demonstrates clinical results comparable to autoinjectors…
Conference Call on Tuesday, November 9, 2021, at 8:30 a.m. ET LEXINGTON, Mass., Oct. 25,…
EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”),…
Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in…
Genetype MultiTest submitted for regulatory approval as commercialization plans gather momentum increase in cash receipts…
The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30…
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate…
Earnings Call taking place at 9:05 a.m. ET expected to include discussion of abstracts accepted…
Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time GARDEN CITY, N.Y., Oct….
Tuesday, November 9th at 11:00 am ET NEWARK, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) —…
Brian DeSchuytner named SVP and Chief Financial Officer CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE)…
Curriculum to help students safely navigate online and thrive in digital world CALGARY, Alberta, Oct….
Google Pixel 6 and Google Pixel 6 Pro are the first smartphone devices certified for…